Biologic Therapeutic Drugs: Technologies and Global Markets
商品番号 : SMB-50198
| 出版社 | BCC Research |
| 出版年月 | 2025年5月 |
| ページ数 | 170 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,650 |
| 種別 | 英文調査報告書 |
本レポートは、世界の生物学的治療薬市場の概要を示し、市場動向を分析しています。2023年の基準年データおよび2024年の推定データの世界売上（百万米ドル）が含まれています。予測期間は2024年から2029年です。
市場は、製品タイプ、用途、ソース、地域に基づいてセグメント化されています。製品別では、モノクローナル抗体、ワクチン、ペプチドホルモン、細胞および遺伝子治療、その他に細分化されています。
ソース別では、哺乳類、微生物、その他に細分化されています。用途別では、腫瘍学、自己免疫疾患、感染症、その他に細分化されています。
本調査でカバーされている地域は、北米、ヨーロッパ、アジア太平洋、中東、アフリカ、南米で、これらの地域の主要国に焦点を当てています。北米地域には、米国、カナダ、メキシコが含まれます。ヨーロッパには、ドイツ、英国、イタリア、フランス、スペイン、その他のヨーロッパが含まれます。アジア太平洋地域には、中国、日本、インド、韓国、およびその他のアジア太平洋地域が含まれます。
Report Highlights
The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.
生物学的治療薬の世界市場は、2024年から2029年にかけて年平均成長率（CAGR）9.7%で拡大し、2024年の4,992億ドルから2029年には7,945億ドルに達すると予測されています。
Summary:
The pharmaceutical industry is undergoing tremendous transformations by focusing more on targeted and personalized therapies. The industry is witnessing a shift from traditional synthetic drugs to biologic therapeutic drugs, which are more efficacious, have better patient outcomes and improve quality of life. Biologic drugs are primarily classified into monoclonal antibodies; vaccines; peptide hormones; cell and gene therapies; and others, which include protein therapeutics (e.g., cytokines, enzymes, blood factors, fusion proteins) and other drugs (e.g., RNA-based therapies).
製薬業界は、標的治療と個別化治療への注力により、大きな変革期を迎えています。従来の合成医薬品から、より有効性が高く、患者の転帰を改善し、生活の質を向上させる生物学的製剤への移行が進んでいます。生物学的製剤は主に、モノクローナル抗体、ワクチン、ペプチドホルモン、細胞・遺伝子治療薬、そしてタンパク質治療薬（サイトカイン、酵素、血液因子、融合タンパク質など）やその他の薬剤（RNAベースの治療薬など）に分類されます。
The biopharmaceutical industry has recently been witnessing tremendous growth due to the increasing demand for innovative therapies, such as monoclonal antibodies, cell and gene therapies and vaccines. The demand for these therapies is primarily driven by such factors as the increasing prevalence of chronic diseases, rising healthcare expenditures, increasing awareness, novel product launches and strong pipelines. The biologic approvals by the U.S. Food and Drug Administration (FDA) are increasing year on year, and 2023 was marked by the approval of two breakthrough therapies: the gene editing therapy Casgevy from Vertex Pharmaceutical and Leqembi (lecanemab) from Eisai Inc.
The global biologic therapeutic drug market was valued at $456.9 billion in 2023, and it is expected to grow at a compound annual growth rate (CAGR) of 9.7% during the forecast period from 2024 to 2029. The entry of biosimilars into the market is expected to erode the revenues of the current branded products upon patent expiry. The complex manufacturing process, a lack of skilled workforce and high development costs translate to a high cost of therapy, which acts as a major barrier to the market.
Report Scope
This report provides an overview of the global biologic therapeutic drug market and analyzes market trends. It includes global revenue ($U.S. millions) for base year data for 2023 and estimated data for 2024. The forecast period is 2024 through 2029. The market is segmented based on product type, application, source and region. By product, the market is segmented into monoclonal antibodies, vaccines, peptide hormones, cell and gene therapies and others. By source, it is segmented into mammalian, microbial and others. By application, the market is segmented into oncology, autoimmune diseases, infectious diseases and others. The regions covered in this study are North America, Europe, Asia-Pacific, Middle East and Africa, and South America, focusing on the major countries in these regions. The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, South Korea and the Rest of Asia-Pacific.
The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape, which provides the ranking and share of key players in the global biologic therapeutic drug market. It also has a section dedicated to company profiles that covers such details as overview, key financials, product portfolio and recent developments of key market players.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2023 | ||||||||||||||||
| Forecast period considered | 2024-2029 | ||||||||||||||||
| Base year market size | $456.9 billion | ||||||||||||||||
| Market size forecast | $794.5 billion | ||||||||||||||||
| Growth rate | CAGR of 9.7% for the forecast period of 2024-2029 | ||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||
| Segments covered | Type, Source, Application, Region | ||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, Rest of the World | ||||||||||||||||
| Countries covered | U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, China, India, Japan, Australia, South America, Middle East and Africa | ||||||||||||||||
| Key Market Drivers |
| ||||||||||||||||
| Companies studied |
| ||||||||||||||||
Report Includes
– 49 data tables and 58 additional tables
– An overview of the current and future global markets for biologic therapeutic drugs and technologies
– An analysis of the global market trends, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
– Estimates of the size and revenue prospects of the global market, along with a market share analysis by product type, application, source and region
– Facts and figures pertaining to market dynamics, technological advances, regulations, and the impact of macroeconomic factors
– Evaluation of the ongoing clinical trials and R&D activity for biologics production
– A look at the key drugs on the market and recent approvals, sales statistics and past performance of the top-selling biologics
– An analysis of patents, emerging trends and other developments in the industry
– Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
– Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
– Company profiles of major players within the industry, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Pfizer Inc., and Bristol-Myers Squibb Co.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Technological Advances
Conclusion
Chapter 2 Market Overview
Overview
Biologic and Synthetic Drug Comparison
Biologic Manufacturing
Biopharmaceutical Manufacturing Process
Macroeconomic Factors Analysis
Porter’s Five Forces Analysis
Supply Chain Analysis
Cell and Gene Therapy Supply Chain
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Growing Demand for Biologics
Rising Investments in Biopharmaceuticals
Product Development Collaborations and Agreements
Transition Toward Personalized Medicines
Rising Aging Population and the Growing Prevalence of Chronic Diseases
Market Restraints
Emergence of Biosimilars
Complex Manufacturing, Lack of Skilled Professionals and High Production Costs
Market Opportunities
Rising Demand for Biopharmaceuticals in Emerging Countries
Technological Innovations in Biologics
Chapter 4 Regulatory Landscape
U.S. Approval Process
European Union Approval Process
Asia-Pacific Approval Process
Chapter 5 Emerging Technologies and Developments
Emerging Technologies
Advances in Monoclonal Antibodies
Antibody-Drug Conjugates
Bispecific Antibodies
Nanobodies
Single-Chain Variable Fragments Antibodies
Antibody Mimetics
Antibody Fusion Proteins
Advances in Vaccines
Advances in Cell and Gene Therapies
Chapter 6 Market Segmentation Analysis
Overview
Segmentation Breakdown
Market Analysis by Product Type
Monoclonal Antibodies
Vaccines
Peptide Hormones
Cell and Gene Therapy
Others
Market Analysis by Source Type
Mammalian
Microbial
Others
Market Analysis by Application
Oncology
Autoimmune Disease
Infectious Diseases
Others
Geographic Breakdown
Market Analysis by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Overview
Highest Selling Biologic Therapeutic Drugs
Market Share Analysis
Monoclonal Antibodies
Vaccines
Peptide Hormones
Cell and Gene Therapy
Strategic Initiatives
Agreements, Collaborations and Partnerships
Acquisitions
Other Strategies
Chapter 8 Sustainability in Biologics Therapeutic Drug Market: An ESG Perspective
Introduction to ESG
Sustainability Trends and Initiatives
Environmental
Social and Governance Initiatives
ESG Risk Ratings
Concluding Remarks
Chapter 9 Appendix
Research Methodology
Emerging Start-ups/Market Disruptors
Sources
Abbreviations
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
ELI LILLY AND CO.
HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC.
JOHNSON & JOHNSON SERVICES INC.
MERCK & CO. INC.
NOVARTIS AG
NOVO NORDISK A/S
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
List of Tables
Summary Table : Global Market for Biologic Therapeutic Drugs, by Region, Through 2029
Table 1 : Global Incidence and Mortality Cancer Rates, by the WHO Region, 2022
Table 2 : Global Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 3 : Top-Selling Monoclonal Antibodies, in 2023
Table 4 : Global Market for Monoclonal Antibodies, by Region, Through 2029
Table 5 : Global Market for Vaccines, by Region, Through 2029
Table 6 : Global Market for Peptide Hormones, by Region, Through 2029
Table 7 : Cell and Gene Therapy Approvals, 2023 and 2024
Table 8 : Global Market for Cell and Gene Therapy, by Region, Through 2029
Table 9 : Global Market for Other Biologic Drugs, by Region, Through 2029
Table 10 : Global Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 11 : Global Market for Mammalian Cells, by Region, Through 2029
Table 12 : Global Market for Microbial Cells, by Region, Through 2029
Table 13 : Global Market for Other Cells, by Region, Through 2029
Table 14 : Global Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 15 : Global Market for Biologic Therapeutic Drugs in Oncology, by Region, Through 2029
Table 16 : Global Market for Biologic Therapeutic Drugs for Autoimmune Diseases, by Region, Through 2029
Table 17 : Global Market for Biologic Therapeutic Drugs for Infectious Diseases, by Region, Through 2029
Table 18 : Global Market for Biologic Therapeutic Drugs for Other Diseases, by Region, Through 2029
Table 19 : Global Market for Biologic Therapeutic Drugs, by Region, Through 2029
Table 20 : North American Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 21 : North American Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 22 : North American Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 23 : North American Market for Biologic Therapeutic Drugs, by Country, Through 2029
Table 24 : FDA-Approved Biologics, 2023
Table 25 : European Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 26 : European Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 27 : European Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 28 : European Market for Biologic Therapeutic Drugs, by Country, Through 2029
Table 29 : Asia-Pacific Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 30 : Asia-Pacific Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 31 : Asia-Pacific Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 32 : Asia-Pacific Market for Biologic Therapeutic Drugs, by Country, Through 2029
Table 33 : Biologics Approved in China, in 2023
Table 34 : Rest of the World Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 35 : Rest of the World Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 36 : Rest of the World Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 37 : Rest of the World Market for Biologic Therapeutic Drugs, by Sub-Region, Through 2029
Table 38 : Agreements, Collaborations and Partnerships in the Biologic Therapeutic Drug Market, 2022-2025
Table 39 : Acquisitions in the Biologic Therapeutic Drug Market, 2022-2024
Table 40 : Others Strategic Initiatives in the Biologic Therapeutic Drug Market, 2022-2024
Table 41 : Environmental Initiatives by Various Biologic Therapeutic Drug Manufacturers
Table 42 : Key Social and Governance Issues Biologic Therapeutic Drug Market
Table 43 : ESG Risk Rankings for Biologic Therapeutic Drug Companies, 2023
Table 44 : List of a Few Emerging Startups in the Biologic Therapeutic Drugs Market
Table 45 : Information Sources in this Report
Table 46 : Abbreviations Used in the Global Biologic Therapeutic Drugs Market
Table 47 : AbbVie Inc.: Company Snapshot
Table 48 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 49 : AbbVie Inc.: Product Portfolio
Table 50 : AbbVie Inc.: News/Key Developments, 2022–2024
Table 51 : Amgen Inc.: Company Snapshot
Table 52 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 53 : Amgen Inc.: Product Portfolio
Table 54 : Amgen Inc.: News/Key Developments, 2021-2024
Table 55 : AstraZeneca: Company Snapshot
Table 56 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 57 : AstraZeneca: Product Portfolio
Table 58 : AstraZeneca: News/Key Developments, 2021−2024
Table 59 : Bristol-Myers Squibb Co.: Company Snapshot
Table 60 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 61 : Bristol-Myers Squibb Co.: Product Portfolio
Table 62 : Bristol-Myers Squibb Co.: News/Key Developments, 2022–2025
Table 63 : Eli Lilly and Co.: Company Snapshot
Table 64 : Eli Lilly and Co.: Financial Performance, FY 2023 and 2024
Table 65 : Eli Lilly and Co.: Product Portfolio
Table 66 : Eli Lilly and Co.: News/Key Developments, 2023 and 2024
Table 67 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 68 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 69 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 70 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022–2025
Table 71 : Gilead Sciences Inc.: Company Snapshot
Table 72 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 73 : Gilead Sciences Inc.: Product Portfolio
Table 74 : Gilead Sciences Inc.: News/Key Developments, 2022−2024
Table 75 : GSK PLC.: Company Snapshot
Table 76 : GSK PLC.: Financial Performance, FY 2023 and 2024
Table 77 : GSK PLC.: Product Portfolio
Table 78 : GSK PLC.: News/Key Developments, 2024
Table 79 : Johnson & Johnson Services Inc.: Company Snapshot
Table 80 : Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
Table 81 : Johnson & Johnson Services Inc.: Product Portfolio
Table 82 : Johnson & Johnson Services Inc.: News/Key Developments, 2022−2024
Table 83 : Merck & Co. Inc.: Company Snapshot
Table 84 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 85 : Merck & Co. Inc.: Product Portfolio
Table 86 : Merck & Co. Inc.: News/Key Developments, 2022–2024
Table 87 : Novartis AG: Company Snapshot
Table 88 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 89 : Novartis AG: Product Portfolio
Table 90 : Novartis AG: News/Key Developments, 2022-2025
Table 91 : Novo Nordisk A/S: Company Snapshot
Table 92 : Novo Nordisk A/S: Financial Performance, FY 2023 and 2024
Table 93 : Novo Nordisk A/S: Product Portfolio
Table 94 : Novo Nordisk A/S: News/Key Developments, 2021–2025
Table 95 : Pfizer Inc.: Company Snapshot
Table 96 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 97 : Pfizer Inc.: Product Portfolio
Table 98 : Pfizer Inc.: News/Key Developments, 2023–2024
Table 99 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 100 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 101 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 102 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024
Table 103 : Sanofi: Company Snapshot
Table 104 : Sanofi: Financial Performance, FY 2023 and 2024
Table 105 : Sanofi: Product Portfolio
Table 106 : Sanofi: News/Key Developments, 2022–2024
List of Figures
Summary Figure : Global Market Shares of Biologic Therapeutic Drugs, by Region, 2023
Figure 1 : Differences Between Synthetic and Biologic Drugs
Figure 2 : Porter’s Five Forces Analysis of the Biologic Therapeutic Drugs Market
Figure 3 : Supply Chain of Biopharmaceutical Drugs
Figure 4 : Market Dynamics of Biologic Therapeutic Drugs
Figure 5 : Venture Averages for Biopharma Therapeutics and Platform Companies, 2010–2024
Figure 6 : Personalized Medicines’ Contribution to the Total FDA Approvals, 2015–2023
Figure 7 : Emerging Technologies in Monoclonal Antibodies
Figure 8 : Global Market Shares of Biologic Therapeutic Drugs, by Product Type, 2023
Figure 9 : Global Vaccination Coverage, by Vaccine, 2023
Figure 10 : Global Market Shares of Biologic Therapeutic Drugs, by Source Type, 2023
Figure 11 : Global Market Shares of Biologic Therapeutic Drugs, by Application Type, 2023
Figure 12 : Global Market Shares for Biologic Therapeutic Drugs, by Region, 2023
Figure 13 : North American Market Shares of Biologic Therapeutic Drugs, by Country, 2023
Figure 14 : European Market Shares of Biologic Therapeutic Drugs, by Country, 2023
Figure 15 : Asia-Pacific Market Shares of Biologic Therapeutic Drugs, by Country, 2023
Figure 16 : Rest of the World Market Shares of Biologic Therapeutic Drugs, by Sub-Region, 2023
Figure 17 : Top 10 Blockbuster Biologic Therapeutic Drugs, by Sales Revenue, 2023
Figure 18 : Global Market Shares for Monoclonal Antibodies, by Key Players, 2023
Figure 19 : Global Market Shares for Vaccines, by Key Players, 2023
Figure 20 : Global Market Shares for Peptide Hormones, by Key Players, 2023
Figure 21 : Global Market Shares for Cell and Gene Therapy, by Key Players, 2023
Figure 22 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
Figure 23 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
Figure 24 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
Figure 25 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 26 : AstraZeneca: Revenue Share, by Business Unit, FY 2024
Figure 27 : AstraZeneca: Revenue Share, by Region/Country, FY 2024
Figure 28 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
Figure 29 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
Figure 30 : Eli Lilly and Co.: Revenue Share, by Business Unit, FY 2024
Figure 31 : Eli Lilly and Co.: Revenue Share, by Country/Region, FY 2024
Figure 32 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 33 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 34 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2024
Figure 35 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2024
Figure 36 : GSK PLC.: Revenue Share, by Business Unit, FY 2024
Figure 37 : GSK PLC.: Revenue Share, by Country/Region, FY 2024
Figure 38 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2024
Figure 39 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2024
Figure 40 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2024
Figure 41 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2024
Figure 42 : Novartis AG: Revenue Share, by Business Unit, FY 2024
Figure 43 : Novartis AG: Revenue Share, by Country/Region, FY 2024
Figure 44 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2024
Figure 45 : Novo Nordisk A/S: Revenue Share by Country/Region, FY 2024
Figure 46 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
Figure 47 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
Figure 48 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
Figure 49 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2024
Figure 50 : Sanofi: Revenue Share, by Business Unit, FY 2024
Figure 51 : Sanofi: Revenue Share, by Country/Region, FY 2024
BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。
ライセンス別価格表
2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
新価格表
ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 4,650 | USD 5,580 | USD 6,696 | USD 8,035 |
ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,950 | USD 3,540 | USD 4,248 | USD 5,098 |
ライセンスタイプ3
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,500 | USD 3,000 | USD 3,600 | USD 4,320 |
旧価格表
旧ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 5,500 | USD 6,600 | USD7.920 | USD 9,504 |
旧ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 3,500 | USD 4,200 | USD 5,040 | USD 6,048 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- 2-5ライセンス
- 同一企業内5名までレポートファイルのご利用が可能です。
- サイトライセンス
- 同一企業同住所内でレポートファイルのご利用が可能です。
- エンタープライズライセンス
- 同一企業内人数無制限でレポートファイルのご利用が可能です。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- ご注文後3営業日以内
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自律型無人潜水機の2030年までの世界市場 2025-06-06
- 世界のSDV(ソフトウェア・デファインド・ビークル)市場 2025-06-06
- 高分子発泡体の世界市場 2025-06-06
- 世界の細胞株と細胞膜市場 2025-06-05
- 世界のエッジAI市場 2025-06-03
